<DOC>
	<DOCNO>NCT01617239</DOCNO>
	<brief_summary>The goal study assess safety immune response vaccination different dos vaccination schedule virosomal influenza vaccine .</brief_summary>
	<brief_title>Clinical Study Safety Immunogenicity Study Influenza Vaccine</brief_title>
	<detailed_description>Virosomal influenza vaccine usually administer intramuscularly single 0.5 mL dose . The aim study evaluate safety immunogenicity different dos vaccination schedule . A total 84 healthy adult age 18-50 year randomize ( 1:1:1 ) 3 treatment group : subject group 1 receive standard dose ( 0.5 mL ) Days 1 , 29 , 57 ; subject group 2 receive double dose ( 1.0 mL ) Day 1 standard dose ( 0.5 mL ) Day 57 ; subject group 3 receive triple dose ( 0.5 mL ) Day 1 . Local systemic solicit adverse event Day 4 vaccination document . To assess subject ' humoral cellular immune response homologous heterologous virus strain , blood drawn participant baseline ( Day 1 ) , 4 subsequent monthly visit ( Months 1 4 ) Month 12 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female adult Aged ≥ 18 ≤ 50 year day enrollment Written inform consent Female subject childbearing potential use willing continue use acceptable method contraception unless surgically sterilized/hysterectomized postmenopausal 2 year Acute exacerbation bronchopulmonary infection ( cough , sputum , lung finding ) acute disease Body weight 40 kg visit study Acute febrile illness ( ≥ 38.0°C ) Known hypersensitivity vaccine component Previous history serious adverse reaction influenza vaccine Previous vaccination seasonal influenza vaccine season 20112012 virosomal formulation seasonal influenza vaccine season History egg protein allergy severe atopy Known blood coagulation disorder Chronic ( longer 14 day ) administration immunosuppressant immunemodifying drug within 6 month first dose study vaccine , include oral corticosteroid dosage ≥ 0.5 mg/kg/d prednisolone equivalent ( inhaled topical steroid allow ) Known immunodeficiency ( incl . leukemia , HIV seropositivity ) cancer Known history psychiatric disease , particularly dementia Investigational medicinal product receive past 3 month ( 90 day ) Treatment immunoglobulin blood transfusion ( ) receive past 3 month ( 90 day ) Pregnancy lactation Participation another clinical trial entire duration trial Employee investigational site relative investigator Subjects view investigator comply study procedure and/or visit requirement per protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Virosomal influenza vaccine</keyword>
</DOC>